417722-93-1
4-(4-Amino-3-chlorophenoxy)-7-methoxyquinoline-6-carboxamide
CAS: 417722-93-1
Molecular Formula: C17H14ClN3O3
417722-93-1 - Names and Identifiers
417722-93-1 - Physico-chemical Properties
| Molecular Formula | C17H14ClN3O3 |
| Molar Mass | 343.76 |
| Density | 1.407±0.06 g/cm3(Predicted) |
| Melting Point | >193°C (dec.) |
| Boling Point | 577.2±50.0 °C(Predicted) |
| Solubility | Chloroform (Slightly), Methanol (Slightly) |
| Appearance | Solid |
| Color | Purple to Very Dark Purple |
| pKa | 15.46±0.30(Predicted) |
| Storage Condition | Keep in dark place,Sealed in dry,Room Temperature |
| MDL | MFCD29072801 |
417722-93-1 - Reference Information
| Overview | Lenvatinib (Lenvatinib,1) the chemical name is 4-[3-chloro-4-(cyclopropylaminocarbonyl) aminophenoxy]-7-methoxy-6-quinolinecarboxamide, is Japanese Eisai the company developed an oral multi-receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activity of vascular endothelial growth factor (VEGF) receptors VEGFR1,VEGFR2, and vegfr3, it is mainly used for the treatment of differentiated thyroid carcinoma (DTC). The drug was approved by the US FDA for marketing on February 13, 2015 under the trade name Lenvima. In July 2015, the FDA further granted the breakthrough drug qualification of lenvatinib for the treatment of advanced and/or metastatic renal cell carcinoma. The lenvatinib impurity is an intermediate in the synthesis of lenvatinib, and is also an important impurity in the synthesis of lenvatinib. |
Last Update：2024-04-09 02:00:14
Supplier List
Spot supply
Product Name: Lenvatinib Impurity 3 Visit Supplier Webpage Request for quotationCAS: 417722-93-1
Tel: 0714-3999186
Email: 2853786052@qq.com
Mobile: 86+15671228036
QQ: 2853786052
Wechat: 15671228036
Spot supply
Product Name: Lenvatinib Impurity 3 Visit Supplier Webpage Request for quotationCAS: 417722-93-1
Tel: 0714-3999186
Email: 2853786052@qq.com
Mobile: 86+15671228036
QQ: 2853786052
Wechat: 15671228036
View History